Drug intelligence / Profile preview

Den-PEG

Development stage: Preclinical
Modality: Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

Den-PEG is a G5 dendrimer conjugated with polyethylene glycol (PEG), functioning as a core component of a novel multimodal nanoprobe. This nanoprobe is engineered for the imaging of tiny hepatocellular carcinoma (HCC) by serving as a scaffold for aptamers and imaging reporters. The aptamers specifically target endoglin (CD105), a protein highly expressed in HCC cells and neovasculature. The nanoprobe facilitates the visualization of orthotopic HCC xenografts through near-infrared (NIR) fluorescence imaging and T1-weighted magnetic resonance imaging (MRI), allowing for the clear delineation of tumor margins.

Other names: PEGylated dendrimerpolyamidoamine-polyethylene glycol conjugatePAMAM-PEG nanoparticle

Targets

ENG (Integrin Beta 6)

Beyond the preview

Go deeper on Den-PEG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Den-PEG.

Explore the full profile